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Palavras-chave Caquexia; cancro da cabeça e pescoço; catabolismo; lipólise;  
remodelação do tecido adiposo 
Resumo O cancro da cabeça e pescoço está associado a uma elevada mortalidade e 
morbilidade, e acredita-se que 50% dos pacientes com este tipo de cancro 
experienciem uma perda de peso significativa numa fase avançada de 
doença, uma condição designada de caquexia. A patofisiologia da caquexia 
associada ao cancro é complexa e envolve mediadores produzidos pelo 
tumor ou pelo hospedeiro em resposta ao tumor, que induzem alterações 
sistémicas que culminam na perda de peso e consequente perda da qualidade 
de vida. Com o objetivo de melhor compreender os mecanismos moleculares 
subjacentes à caquexia associada ao cancro da cabeça e pescoço, no presente 
trabalho colectamos dados clínicos e analisamos amostras de soro de 17 
pacientes com carcinoma espinocelular na orofaringe ou hipofaringe, com e 
sem caquexia (determinada com base na perda de peso corporal superior a 
5% nos 6 meses anteriores). 
Os resultados obtidos permitiram verificar que o índice de massa corporal 
bem como o estadio do tumor (T3 e T4 em ambos os grupos) não se 
relacionam com a presença de caquexia, apesar de os índices  nutricionais 
MUST e PG-SGA serem mais elevados nos doentes com perda de peso 
corporal superior a 5% em 6 meses. Mais ainda, não se observaram 
diferenças significativas de marcadores bioquímicos indicativos de 
alterações metabólicas associadas à remodelação do tecido adiposo. Os 
níveis séricos da citocina pró-inflamatória TWEAK e da proteína de fase 
aguda CRP não foram significativamente diferentes entre os 2 grupos de 
pacientes, bem como os níveis das adipocinas, leptina e adiponectina e da 
hormona gástrica grelina. No entanto, observaram-se níveis séricos da 
citocina catabólica miostatina significativamente mais elevados nos 
pacientes com caquexia, o que sugere que o catabolismo muscular contribui 
para o desenvolvimento desta síndrome paraneoplásico. 
Em resumo, os resultados obtidos no presente estudo não suportam a 
contribuição da remodelação do tecido adiposo para o desenvolvimento de 
caquexia mas evidenciam a importância do catabolismo muscular para a 
perda de peso corporal nos doentes com cancro da cabeça e pescoço. Estudos 
futuros envolvendo mais grupos de doentes e mais doentes por grupo serão 
importantes para melhor compreender a contribuição da remodelação do 
tecido adiposo na patogénese da caquexia associada ao cancro da cabeça e 
pescoço. 
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Keywords Cachexia; head and neck cancer; wasting; lipolysis; WAT 
remodelling 
Head and neck cancer (HNC) is a significant cause of cancer morbidity 
and mortality worldwide and it is believed that 50% of HNC patients 
experience significant weight loss at an advanced stage of the disease, 
a condition known as cachexia. The pathophysiology of cancer 
cachexia is complex and involves several mediators produced by the 
tumour or the host that induce body weight loss and, consequently, 
impairs quality of life. In this thesis project we aimed to better 
comprehend the molecular mechanisms underlying cachexia in HNC 
by evaluating clinical and biochemical parameters from 17 patients 
with squamous cell carcinoma at oropharynge and hypopharing, with 
and without cachexia (assessed by body weight loss higher than 5% in 
6 months).  
Our results showed no association between body mass index and 
tumour staging with the establishment of cachexia in head and neck 
cancer, despite the higher scores of MUST and PG-SGA observed in 
patients with body weight loss higher than 5% in 6 months. No 
apparent metabolic changes associated with adipose tissue remodelling 
were detected among patients‘ groups. The levels of TWEAK and CRP 
were not significantly different among the 2 groups of patients, not 
supporting the contribution of inflammation to the development of 
cachexia. The serum levels of the adipokines leptin and adiponectin, 
and of the gastric hormone ghrelin do not evidence the contribution of 
WAT remodelling to the head and neck cancer-related body weight 
loss. However, the significantly higher serum levels of myostatin in the 
group of patients with body weight loss higher than 5% in 6 months 
highlights the contribution of muscle wasting to the cachexia 
phenotype in head and neck cancer. 
Taken together, our results evidence the contribution of muscle 
wasting but not of WAT remodelling to the development of cachexia 
in the set of head and neck cancer. Future studies involving a higher 
number of patients and more groups of patients will be important to 
better follow WAT remodelling and its interplay with muscle wasting 
in the pathogenesis of head and neck cancer.  
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I. Introduction 
 
Head and neck squamous cell carcinoma (HNSCC) is a significant cause of 
morbidity and mortality by cancer worldwide with rates of incidence varying around the 
world and with a global incidence of 500,000 cases per year with the highest rates being 
found in Southeast Asia and Eastern Europe (Brennan et al., 1995; Hardisson, 2003; 
Kreimer et al., 2005). In Portugal, HNSCC is one of the most common cancers 
worldwide, constituting the fifth cause of death with cancer among men (Silveira et al., 
2010). In the western world a decline of its incidence has been observed and attributed 
to the population‘s awareness of the risk factors, such as smoking and alcohol abuse. On 
the other hand an increase in oral tongue and oropharyngeal cancer has been noticed, 
which may be connected with an increase of human papilloma virus (HPV) related 
infections (Leemans et al., 2011). 
 HNSCC is a complex disease, characterized by clinical, pathological, 
phenotypical and biological heterogeneity with origins in genetic and epigenetic 
alterations that lead to hyperplasia of squamous epithelium, dysplasia, carcinoma in situ 
and, eventually, cancer (Haddad et al., 2008; Leemans et al., 2011). The current view of 
HNSCC onset relies in three main genetic alterations, that comprise the inactivation of 
the p53 tumour suppressor gene, the inactivation of the cyclin dependent kinase 
inhibitor 16 and the overexpression of epidermal growth factor receptor (EGFR) 
(Douglas et al., 2004). 
 In spite of the advances made in the clinical management of HNSCC, the 
survival rate after diagnosis is still low, being lower than in other types of cancer , and 
the major cause of death being  cervical node and distant metastasis (John et al., 2009; 
Molinolo et al., 2009). The treatment and prognosis of HNSCC varies with the stage of 
the disease, anatomic site and, in the case of prognosis, with patient‘s response to the 
treatment. The therapeutic approaches usually involve surgery, radiotherapy and may 
also involve chemotherapy; however, the main treatment is surgical resection. The 
presence of positive pathologic lymph nodes strongly influences the prognosis (Brennan 
et al., 1995; Leemans et al., 2011; Rhys‐Evans et al., 2001). Some molecular markers,  
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such as HPV infection and tumour markers, as well as genetic polymorphisms might 
also be used to predict the outcome of the disease (Brennan et al., 1995; Hopkins et al., 
2008). The presence of body wasting also influences disease prognosis (Cabal-Manzano 
et al., 2001; Ebadi et al., 2014; Tisdale, 2002). 
 Cells of HNSCC develop molecular strategies that allow them to evade growh 
inhibitory effects of cytokines that are present in the microenvironment of the tumour, 
therefore, in this disease the ability of a tumour to become malign is associated with an 
altered response to cytokine stimulation (Pries et al., 2006). Recent studies report an 
increase in the production of inflammatory mediators, such as cytokines, induced by the 
tumour that can lead to increased tumour promotion and invasion, angiogenesis and 
metastasis (John et al., 2009 1). Among the HNSCC-derived pro-inflammatory 
mediators are interleukin  IL-1, IL-4, IL-6, IL-8, granulocyte macrophage-colony-
stimulating factor (GM-CSF), vascular endothelial growth factor (VEGF), prostaglandin 
E2 (PGE2) and fibroblast growth factors (FGF) (Pries et al., 2006). IL-1 has been shown 
to play an important role by inducing the activation of signal transduction pathways, 
involved in the transcription of proinflammatory cytokines genes (John et al., 2009). 
Another major player in HNSCC cases is epidermal growth factor receptor (EGFR), 
since it has been demonstrated elevated levels of EGFR in this disease and elevated 
activity of polypeptide growth factor tyrosine kinase receptor. Consequently, many 
downstream intracellular targets of EGFR are activated, which stimulate tumour 
proliferation, apoptosis, angiogenesis and cell migration/invasion (John et al., 2009; 
Schmitz, 2010 ; Squarize et al., 2006). 
Head and neck cancer patients experience a significant weight loss related with 
the disease and the treatment itself, that has been attributed to a multifactorial metabolic 
syndrome, best known as cachexia (Gorenc et al., 2015; Mason et al., 2016; Wang et al., 
2016). Indeed it is believed that more than 50% of HNSCC patients at an advanced 
stage of the disease experience weight loss and possibly cachexia (Couch et al., 2007; 
Couch et al., 2015). The presence of cachexia greatly contributes to poor prognosis with 
a negative impact in the quality of life of cancer patients. Apart from this it is also 
associated with  physical, psychological and social problems (Couch et al., 2015).To the 
best of our knowledge, cachexia is most of the times underestimated in the clinical 
 
 
 
3 
 
Figure 1. Cachexia as a multi-organ syndrome (Prieto-Hontoria et al., 2011). 
management of HNSCC. Nevertheless, cancer patients would certainly benefit from 
multimodal therapies also targeting cachexia. 
 
1. Cancer associated cachexia: definition and staging   
  
The term cachexia is derived from the Greek ―kakos hexis‖, which means bad 
condition and is, by definition, a metabolic syndrome associated with illness and 
characterized by loss of muscle and adipose tissue (Das et al., 2011; Tisdale, 2005; 
Evans, 2008 ). This paraneoplastic syndrome accounts for 20% of cancer deaths, with 
up to one third of the cachectic patients losing more than 5% of their original body 
weight (Mendes et al., 2015; Tisdale, 2002; Agustsson, 2012 ). Cachexia is usually 
associated with particular types of cancer, predominantly those of pancreas, 
gastrointestinal tract, non-Hodgkin´s lymphoma, prostate, lungs and head and neck. 
Patients with these tumours experience the greatest degree of weight loss (Mendes et al., 
2015; Tisdale, 2002; Tisdale, 2005 ). This condition can arise in a patient with a tumour 
comprising less than 0.01% of the host weight, although some large tumours do not 
produce cachexia (Tisdale, 2003). Apart from the loss of skeletal muscle and adipose 
tissue, cachexia also includes symptoms such as anorexia, hypoglycaemia, anaemia and 
asthenia (Mondello et al., 2015). Symptoms like asthenia (or lack of muscular strength), 
reflect the muscle wasting that takes place in cachectic cancer patients (Argilés et al., 
2003; Strassmann et al., 1992; Theologides, 1979 ). Recent findings suggest the 
involvement of other organs such as brain, liver, gut and heart (figure 1). 
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Since cancer cachexia has become clinically relevant some authors proposed the 
staging of this syndrome in three clinically relevant stages: pre-cachexia, cachexia and 
refractory cachexia, even though not all patients experience all three stages of the 
disease. Pre-cachexia is characterized by early clinical and metabolic signs, such as 
anorexia, inflammation and metabolic alterations. It precedes a weight loss of 
approximately 5% or less (Argilés et al., 2011; Fearon, 2011 ). It includes patients with 
anorexia and chronic systemic inflammation. The presence of inflammation is indicated 
by elevated serum levels of C-reactive protein (CRP) (Muscaritoli et al., 2010). The risk 
of progression varies and depends on the cancer type and stage, the presence of 
systemic inflammation, low food intake and lack of response to anticancer therapy. A 
patient is characterized as having cachexia if presents a body weight loss greater than 
5% over 6 months or has on-going weight loss of more than 2%. In the last stage, the 
cachexia can be clinically refractory as a result of very advanced cachexia or of rapidly 
progressive cancer, which is unresponsive to therapy (Fearon et al., 2011).  
The reduced food intake experienced by cachectic patients has anorexia as a 
major factor and, in most cases, catabolic factors induced by an abnormal host response 
to tumour and/or tumour factors (Bosaeus, 2008).  Apart from anorexia, the loss of lean 
tissue, also characteristic of cachexia might be difficult to detect because of the 
accumulation of water, which might disguise the early changes. This water retention 
may occur as a consequence of hypoalbuminemia and may account for an increase in 
body weight (Tisdale, 2002; Muscaritoli, 2010 ). The imbalance between anabolism and 
catabolism within skeletal muscle seems to be responsible for the accelerated muscle 
loss, leading to muscle weakness, fatigue, immobility and, ultimately, death due to loss 
of respiratory muscle function. Death normally occurs when weight loss is about 30% 
(Tisdale, 2002; Muscaritoli, 2010 ). 
A methodology was recently proposed for the quantitative assessment of cancer 
cachexia and involves the use of a score known as cachexia score (CASCO). This score 
is calculated taking in consideration the level of weight loss and composition, 
inflammation, metabolic disturbances and immunosuppression, physical performance 
and quality of life (figure 2). Several biochemical parameters are considered for the 
assessment of inflammation and metabolic disturbance, such as plasma CRP, IL-6, 
lactate and triglycerides, whereas handgrip strength and validated questionnaires are 
used for the assessment of physical performance and quality of life. This staging of 
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Figure 2. CASCO staging scale (Argilés et al., 2011). 
The components of this score are body weight and composition (BWC) accounts for 40% of 
the score; Inflammation /metabolic disturbances/immunosuppression (IMD) accounts for 20% 
of the score; Physical performance (PHP) accounts for 15% of the score; Anorexia (ANO) 
accounts for 15% of the score; Quality of life (QOL) accounts for 10% of the score. The value 
calculated in the score allows the staging of the patient in mild, moderate, severe and terminal 
phase. 
cachexia envisions to improve its clinical management through targeted therapies (Blum 
et al., 2014; Tisdale, 2005; Argilés, 2011 ).  
 
 
 
 
 
 
 
 
 
 
2. Tumour-host interplay in cancer cachexia 
 
 
The pathophysiology of cancer cachexia is complex and seems to involve several 
chemical mediators. These mediators can be divided into two groups, produced by the 
host or/and by tumour cells, which includes cytokines such as tumour necrosis factor 
(TNF)-α, IL-1 and IL-6 (figure 3). The first group mostly leads to appetite suppression, 
although TNF-α has also been associated with increased lipolysis, by supressing the 
cleavage of lipoprotein lipase (LPL), and the induction of proteolysis, through the 
ubiquitin-proteasome proteolytic pathway (Tisdale, 2002; Ebadi, 2014). The other 
group includes catabolic products, secreted by tumour cells, such as lymphocyte 
mitogenic factor (LMF), known for acting on the adipose tissue through cyclic 
adenosine monophosphate (cAMP) signalling pathway and proteolysis-inducing factor 
(PIF) that induces proteolysis in skeletal muscle by up-regulating the ubiquitin-
proteasome pathway (Hirai et al., 1998; Skipworth et al., 2007; Tisdale., 2002; Mendes., 
2015 ). Mechanistically, PIF not only promotes protein degradation by increasing the 
levels of ubiquitin-carrier protein and proteasome subunits, but also inhibits protein 
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synthesis through, for example, the activation of the RNA-dependent protein kinase 
(PKR) (Eley et al., 2008; George et al., 2007; Mendes et al., 2015; Argilés, 2005 ). PIF 
was recently linked to the hepatic cytokine production and was shown to activate the 
nuclear factor-κB (NF-kB) in primary cultures of human hepatocytes, which lead to the 
increased production of IL-6, IL-8 and CRP and the decrease in transferrin production 
(George et al., 2007; Argilés, 2005; Tisdale, 2002). Other evidences suggest that PIF 
may be able to induce cellular apoptosis in murine myotubes through caspase activity 
(Skipworth et al., 2007). 
 
 
 
 
Systemic inflammation is believed to play a key role in the pathogenesis of 
cachexia, considering the imbalance between pro-inflammatory cytokines, such as TNF-
α and IL-6, and anti-inflammatory cytokines, such as IL-4 and IL-15 (Muscaritoli et al., 
2010). Some of these cytokines have been proposed as mediators of the metabolic 
changes associated with cachexia, such as host and tumour cell derived TNF-α, because 
of its ability to suppress key metabolic enzymes and induce cachexia in pre-clinical 
models (Theologides, 1979; Fearon, 2006 ). Apart from this, TNF-α and IL-1 are able to 
stimulate PGE2 production in macrophages, fibroblasts and endothelial cells. The 
presence of the tumour results in a persistent host inflammatory response, characterized 
Mediators of 
catabolism 
Derived from the 
tumor 
PIF and LMF 
Derived from the host 
Pro-cachectic: TNF,IL-
6,IL-1,IFN-γ, CNTF 
Anti-cachectic: sIL-6,IL-
10,sTNFR,Il-1ra,IL-4,IL-3,IL-5 
Figure 3. Mediators of cancer-induced body wasting (adapted from (Tisdale, 2002). 
(IL – interleukin; sTNFR – soluble tumour necrosis factor receptor; INF-γ – interferon-γ; 
CNTF – ciliary neurotrophic factor; PIF – proteolysis-inducing factor. LMF – lipid-
metabolizing factor). 
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by the production of T helper 1 cytokines, such as TNF-α, and the induction of an acute-
phase response, which is associated with hypermetabolism (Gordon et al., 1999 ; 
Noguchi et al., 1996).  
This acute-phase response is a systemic reaction to local or systemic 
perturbations in the body homeostasis that could be caused by trauma, infection, injury, 
among others. In the presence of a tumour, local inflammatory cells secrete cytokines, 
into the bloodstream, leading to an increase in the production of positive acute phase 
proteins by the liver (Skipworth et al., 2007; Lelbach, 2007 ; Seelaender, 2012). The 
concentration of acute-phase proteins changes after inflammation increases or decreases 
depending if they are positive or negative proteins, respectively. The positive group 
includes CRP and fibrinogen, whereas the negative group involves albumin and 
transferrin (Fearon et al., 1999). 
 
3.1 Cancer induced muscle wasting  
 
 During periods of diminished food intake, muscle proteins are degraded by the 
organism in order to provide the amino acids used in gluconeogenesis; however, if the 
period of starvation is prolonged, the organism reduces the protein breakdown to 
conserve nitrogen and lean body mass. In cancer patients this ability seems to be absent, 
leading to the depletion of host´s proteins (Argiles et al., 1997). The loss of  
myofibrillar proteins (actin, myosin and troponin) in muscle cells is of great relevance 
in cancer cachexia, as it results in muscle weakness and fatigue (Argilés et al., 2014a; 
Schiaﬂino, 1997 ). Many metabolic alterations are responsible for this loss of muscle 
mass, including the imbalance between protein synthesis and degradation, and amino 
acids metabolism, mainly related to their transport and to branched-chain amino acid 
oxidation, since the tumour has high demands for essential amino acids to support its 
growth. Furthermore, an increase in apoptosis and an impaired capacity for regeneration 
contributes to muscle wasting (Argilés et al., 2014a; Argilés, 1999 ). 
Muscle mass depends on the balance between the rate of protein synthesis and 
degradation (Tisdale, 2002). The decrease in protein synthesis could result from reduced 
plasma insulin concentrations and insulin sensitivity of skeletal muscle or even from the 
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decline in the levels of protein translation, in amino acid supply or in the balance of 
amino acids that are required for protein synthesis. There are three proteolytic pathways 
that are responsible for protein catabolism in skeletal muscle: the lysosomal system, 
which is involved in the proteolysis of extracellular proteins and cell-surface receptors 
and has a key role in cellular function; the cytosolic calcium-regulated calpains, which 
has been demonstrated to be very important in the initial degradation of myofibrillar 
proteins; and the adenosine triphosphate (ATP) ubiquitin-dependent proteolytic 
pathway. Of these three systems, ubiquitin-dependent proteolysis is considered the most 
important for protein degradation in a range of catabolic conditions, including 
starvation, sepsis, metabolic acidosis, severe trauma as well as cancer cachexia, since it 
is believed to be involved in the degradation of abnormal proteins and in the breakdown 
of skeletal muscle proteins (figure 4)  (Cataldo et al., 1996; George et al., 2007; 
Muscaritoli et al., 2006; Schiaﬂino et al., 1997; Tisdale, 2002; Temparis, 1994). 
 
 
Ubiquitin can be found free or conjugated with other cellular proteins. The 
presence of ubiquitin marks the protein for degradation by the 26S proteasome, in an 
ATP-dependent manner. Protein ubiquitination is possible due to the action of three 
enzymes, ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and 
ubiquitin ligase (E3) (figure 5), which levels are closely related with the expression of 
Proteolytic pathways 
Lysosomal system 
Proteolysis of cell surface 
receptors and extracellular 
proteins 
Regulation of cellular 
function 
Cytosolic calcium-
regulated proteins 
Degradation of 
myofibrillar proteins 
Ubiquitin proteolytic 
pathway 
Breakdown of skeletal 
muscle proteins 
Figure 4. Schematic representation of the proteolytic pathways, which are divided in three main 
pathways: lysosomal system, cytosolic calcium-regulated proteins and the most important, the 
ubiquitin proteolytic pathway  (adapted from Tisdale, 2002; Argilés, 2005 ). 
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TNF-α and IL-1. The expression of E3 proteins is related with the activity of the 
ubiquitin-proteasome pathways, since these proteins are responsible for the transference 
of activated ubiquitin from ubiquitin carriers to a lysine residue in the protein target. In 
skeletal muscle, specific E3 ligases are known to regulate ubiquitination: 
atrogin1/MAFbx, and muscle RING-finger protein-1 (MuRF1) (figure 5). Some 
evidences suggest that TNF-α increases the expression of free or conjugated ubiquitin, 
connecting the action of this cytokine with skeletal muscle proteolysis (Argilés et al., 
1999; George et al., 2007; Hasselgren, 1999; Li et al., 2005; Sakuma et al., 2012; 
Tisdale, 2005; Argilés, 2005). 
 
 
 
 
 
 
 
 
 
 
Inflammatory cytokines that are secreted by either immune cells or tumours, 
directly induce signalling pathways that up-regulate enzymes involved in skeletal 
muscle protein turnover (Tisdale, 2005). Current research has found elevated levels of 
proinflammatory cytokines, such as TNF-α, IL-1 and IL6, that leads to the suppression 
of some muscle genes, to the activation of the ubiquitin-proteasome mediated 
proteolysis and to the inhibition of myosin heavy chain genes (George et al., 2007). 
Two established signalling pathways were reported to be activated in skeletal muscle by 
pro-inflammatory mediators, the NF-κB and the p38  mitogen-activated protein kinase 
(MAPK) pathways, known for regulate the attaching of ubiquitin to targeted proteins for 
Figure 5. The ubiquitin proteasome pathway (DeWys, 1982). 
Ub (ubiquitin); Ub-activating enzyme; E2, Ub-conjugating enzyme; E3, Ub-protein 
ligase. 
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elimination (Xu et al., 2011). In normal conditions, NF-kB is inactivated by its 
inhibitory protein kBα (IkB); however, when stimulated by TNF-α a signalling cascade 
is initiated leading to the phosphorylation and ubiquitination of its inhibitor, releasing 
NF-kB to travel to the nucleus and promoting  the up-regulation of E3 ligases (Tisdale, 
2005).  
Recently, a new member of the TNF superfamily has been described, TNF-like 
weak inducer of apoptosis (TWEAK),  that together with its receptor Fn14 (fibroblast 
growth factor inducible 14) have been identified as important regulators of skeletal 
muscle mass (Kumar,  2012).  TWEAK binds to Fn14 receptor and together they induce 
the proliferation of myoblasts and inhibit their differentiation into myotubes, regulate 
cell survival, wound repair, inflammation, angiogenesis and apoptosis. TWEAK induces 
proinflammatory responses and stimulates the expression of chemokines, cytokines, 
adhesion molecules and metalloproteases (MMPs). TWEAK induces muscle atrophy 
through the augmentation of the expression of the ubiquitin E3 ligase MuRF1 and the 
consequent activation of the ubiquitin proteasome pathway. It was also found that 
TWEAK can induce the expression of the components of autophagy-lysosomal system 
(ALS) and activate caspases, especially caspase-3, in cultured myotubes (Dogra et al., 
2007; Tisdale, 2003; Kumar, 2012).   
 
3.2. Cancer cachexia- related fat remodelling  
 
In cancer cachexia, skeletal muscle loss is accompanied by the loss of white 
adipose tissue (WAT) (Argilés et al., 2014a). It has been suggested that mobilization of 
fatty acids often occurs before evidences of weight loss (Esper et al., 2005). Indeed, the 
breakdown of fat seems to precede that of skeletal muscle proteins, and it seems that 
some signals generated during the breakdown of WAT triglycerides may be responsible 
for the activation of muscle proteolysis (Argilés et al., 2014b).  
Adipose tissue is an active secretory organ and a major repository of energy, 
which is responsible for the energy balance, homeostasis, appetite, inflammation, 
insulin sensitivity and angiogenesis. In periods of excessive energy, the adipose tissue 
stores energy in the form of triglycerides and, in periods of lack of energy, they release 
the stored triglycerides in the form of non-esterified fatty acids (or free fatty acids, 
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FFAs). The mass of WAT is regulated by two major pathways: lipolysis (fat 
breakdown) and lipogenesis (fat synthesis) (Arner et al., 2014; Ebadi et al., 2014; 
Tisdale, 2005 ). The dissolution of fat mass results from three different altered 
processes: i) increase in lipolytic activity and consequently in hyperlipemia; ii) decrease 
in the activity of lipoprotein lipase (LPL), the enzyme responsible for the cleavage of 
both endogenous and exogenous triglyceride into glycerol and FFAs which impairs  
lipid uptake in WAT; iii) reduced de novo lipogenesis in adipose tissue resulting in 
decreased esterification and decrease triglyceride deposition (Argiles et al., 1997; 
Argilés et al., 2014a). Some studies have shown that plasma glycerol concentrations 
during fasting are much higher in cancer patients who are experiencing weight loss 
compared with weight-stable individuals, providing further evidence for an increase in 
lipolysis (Tisdale, 2002; Das, 2011 ). Other mechanisms, including impairment in 
adipogenesis, elevated fat oxidation and decreased lipid deposition have also been 
attributed to fat loss in cancer (Ebadi et al., 2014).  
 Elevated lipolysis has been reported to be the main cause of adipose tissue loss 
in cancer patients, even though the underlying specific mechanisms have not been 
clearly defined (Ebadi et al., 2014). An increased expression and activity of the enzyme 
hormone sensitive lipase (HSL) has been reported in cancer cachexia as well as a 
decrease in LPL activity, presumably due to the combined activity of cytokines such as 
TNF-α, IL-6 and IFN-γ, which leads to a decrease in the uptake of exogenous lipids and 
an increase in circulating triglycerides. The infiltration of inflammatory cells, primarily 
macrophages, into WAT promotes the local production of inflammatory mediators, 
initiating a negative set of effects in the adipose tissue function and also may induce fat 
cell death (Rydén et al., 2008). HSL and adipose triglyceride lipase (ATGL), which 
catalyses the first step in triglyceride hydrolysis and formation of diacylglycerol, are 
major enzymes that contribute to triglyceride breakdown in adipose tissue (Ebadi et al., 
2014; Das, 2011 ). Indeed, elevated expression of HSL, either messenger RNA (mRNA) 
or protein, has been reported in cancer cachectic patients compared to weight stable 
ones. HSL activity is regulated by hormones, such as catecholamines and glucagon, 
through a cAMP-mediated process. Binding of hormones to G-protein coupled receptors 
results in the up-regulation of adenylate cyclase, which leads to an increase of 
intracellular cAMP concentrations (Ebadi et al., 2014).  
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The increased mobilization of fat is thought to be related to a specific tumour-
produced compound, lipid-mobilizing factor (LMF), which is mediated by β3 
adrenoceptors. LMF is very similar to a zinc-α-2-glycoprotein (also known as ZAG), 
which can be found both in WAT and in brown adipose tissue (BAT) (Esper et al., 
2005; Sanders, 2004). This glycoprotein can sensitize adipocytes to lipolytic stimuli, by 
increasing the stimulation of G proteins, Gαs, and inhibiting Gαi, and has a direct 
lipolytic effect in WAT, which is mediated by a cyclic AMP-dependent mechanism. 
LMF is responsible for the release of FFAs and glycerol, since it stimulates the 
hydrolysis of triglycerides by increasing the production of adenylate cyclase. The 
glycerol produced goes towards the liver, where it is used in gluconeogenesis, whereas 
FFAs are used by other tissues as an alternative substrate to glucose. ZAG is an 
adipokine and induces lipid utilization, increasing fat oxidation and is also responsible 
for the increased production of the uncoupling protein (UCP)-1 in BAT (Argilés et al., 
2006; Esper et al., 2005; Islam-Alim et al., 2001; Mendes et al., 2015; Argilés, 2014 ; 
Muscaritoli et al., 2006; Sanders et al., 2004; Tisdale, 2009). LMF and ZAG act through 
β-adrenoreceptor, and since β-agonists, such as β2-adrenergenic, are able to stimulate 
hypertrophy in the muscle, it was discovered that LMF can stimulate protein synthesis 
in the myotubes and decrease protein degradation. The main effect was centred on the 
inhibition of the ubiquitin-proteasome pathway, suggesting that the combined action of 
LMF and ZAG are able to protect the skeletal muscle from atrophy and explain why 
loss of fat mass precedes loss of skeletal muscle (Tisdale, 2009). LMF causes a specific 
loss of fat mass, along with a decrease in plasma leptin levels and a significant increase 
of uncoupling proteins UCP-1, UCP-2 and UCP-3 levels in BAT (Esper et al., 2005; 
Sanders, 2004 ). 
The alterations in adipose tissue metabolism include changes in the expression 
of genes involved in the  browning of WAT (Agustsson,  2012). Some authors highlight 
the important role of WAT browning in the development and progression of cancer 
cachexia. The activation of thermogenesis in the interscapular BAT has been reported 
and seems to contribute to the hypermetabolic state of cachexia (Petruzzelli et al., 
2014). Brown adipocytes have a large number of mitochondria and consequently of 
UCP-1, which modulates the oxidative phosphorylation (OXPHOS). The presence of 
UCP-1 renders the inner membrane of the mitochondria permeable; therefore the proton 
gradient is disrupted, and is released as heat, without production of ATP. So, this 
mitochondrial protein switches mitochondrial respiration from ATP generation to 
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thermogenesis (figure 6). UCP-1 serves as a marker for brown fat activation, which can 
be connected with the energy deficiency found in cachectic patients (Argilés et al., 
2005; Argilés, 1999 ; Cypess et al., 2009; Jiménez‐Aranda et al., 2013; Quarta et al., 
2013). Several studies demonstrated that molecular regulators such as peroxisome 
proliferator-activated receptor gama (PPAR), peroxisome proliferator-activated 
receptor-gamma coactivator 1 alpha (PGC1) and pR domain containing 16 (PRDM16) 
are involved in WAT browning. PGC1 is a key transcription factor activated by cold 
adaptation and promotes mitochondrial biogenesis, oxidative phosphorylation and 
directly regulates UCP1 expression. PRDM16 is a transcriptional co-regulator that 
controls the fate of precursor cells between skeletal muscle cells and brown adipocytes. 
When the levels are low, it promotes muscle differentiation whereas its presence in 
brown adipocytes regulates the expression of UCP1 (Tsoli et al., 2016).  
Usually BAT is activated through the exposure to low temperatures that leads to 
the stimulation of the -adrenergic pathway and to the activation of cAMP/PKA 
signalling that in turn, modulate PGC1 levels. However, there are other ways to activate 
BAT, such as through the stimulation of transcription factor forkhead box protein C2 
(FOXC2) that is responsible for the increased mitochondrial biogenesis and 
thermogenesis, through regulation of mitochondrial transcription factor A (TFAM). 
Another ways is through the activation of bone morphogenic protein 7 (BMP7) that 
triggers MAPK p38 pathways and fibroblast growth factor 21 (FGF21), which increases 
thermogenesis in BAT. Furthermore, irisin, an hormone  produced by exercised skeletal 
muscle acts on white adipocyte precursors through MAPKs ERK1/2 and p38 pathways 
(Tsoli et al., 2016).  
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WAT browning in cancer was highlighted by the introduction of staging with 
18
F-fluorodeoxyglucose positron emission tomography (PET) scanning (Petruzzelli et 
al., 2014) (figure 7). Some tumour-induced factors were suggested to be involved in this 
fat remodelling, such as inflammatory cytokines, EGF family members, 
parathyroid‐hormone‐related protein (PTHRP), the irisin and cyclooxygenase (COX2) 
(Jiménez‐Aranda et al., 2013). The phenotypic switch of WAT to BAT and the 
increased energy expenditure was reported to proceed skeletal muscle atrophy in many 
mouse models of cancer cachexia (Petruzzelli et al., 2014). 
Figure 6. Browning of white adipose tissue in cachexia  (based on Argilés,  
2014a).  
In addition to elevated lipolysis, decreased lipogenesis and reduced entry of 
fatty acids owing to decreased activity of LPL are responsible for adipose tissue 
wasting. This represents the ―browning‖ process of white cells, in which UCP-1 
is expressed. UCP-1 promotes heat production and energetic inefficiency. This 
cell conversion can be triggered by both humoral inflammatory mediators, such 
as IL-6 and tumour-derived compounds, such as PTHRP. This figure was made 
with Servier Medical Art. 
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Brown adipocytes induced in WAT are also known as ‗‗beige‘‘ cells, which are 
derived from a population distinct from mature, white and brown, adipocytes (figure 8) 
(Petruzzelli et al., 2014). Unlike WAT, which stores energy as intracellular lipid 
droplets, brown and beige adipocytes are metabolically active and promote energy 
expenditure  (Martz, 2014).  
 
Figure 8. Adipose tissue samples stained with hematoxylin and eosin show the histological differences 
between brown and white adipose tissue. In brown adipose tissue granular cytoplasm containing 
mitochondria and multiple fat vacuoles are observable (Cypess et al., 2009). 
 
Other findings have linked WAT browning to the thyroid system. This enzyme 
is controlled by norepinephrine and is capable of generating triiodothyronine (T3) from 
thyroxine (T4). Intracellular T3 is capable of inducing the transcription of the UCP1 
gene. However, this new finding not only have shed a light in the role of the thyroid in 
this process, but also highlighted a link between the thyroid and the sympathetic 
nervous system (SNS). The presence of 5‘-deiodinase, which is produced after meals, in 
BAT is regulated by bile acids. The liver also releases a fibroblast growth factor-21 
 Figure 7. The figure shows the quantification of the amount and activity of brown adipose in the 
cervical, supraclavicular, and superior mediastinal depots of brown adipose tissue. (PET (left), 
computed tomography (CT, center), and combined PET–CT (right) (Cypess et al., 2009). 
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(FGF21) that interacts with FGF receptor/β-Klotho complexes at the cell surface, 
inducing mitochondrial uncoupled respiration and glucose oxidation. Therefore FGF21 
directly activates heat production by BAT and promotes the WAT browning depots, 
highlighting the importance of liver in this process. The thyroid effects on the 
hypothalamus activates peripheral BAT through the induction of AMP-kinase, leading 
to enhanced activation of the SNS (Villarroya et al., 2013). Moreover, activated 
macrophages are able to control the thermogenic action of BAT via local release of 
catecholamines. This process seems to be similar to the reported in the exposure to cold. 
The exposure to cold was reported to activate the IL-4/IL-13-mediated pathway of 
macrophage activation, within BAT. These activated macrophages produce 
norepinephrine, which was previously referred to as having an important role in the 
thyroid (Villarroya et al., 2013). 
 
 
3.3 Adipokine pathway associated with adipose tissue 
alterations in cancer 
 
Adipokines are cytokines produced by adipose tissue that have an important role 
in energy balance, metabolism and inflammatory responses. Some adipokines such as 
leptin, adiponectin and resistin, participate in systemic inflammatory response, and may 
influence the action of other cytokines, such as TNF-α and IL-6, which makes them able 
not only to regulate inflammation but also angiogenesis, cell proliferation, 
differentiation and migration (Karapanagiotou et al., 2008). Leptin is predominantly 
produced by the adipose tissue but also by the placenta and bone marrow and acts in the 
central nervous system to suppress food intake and regulate energy homeostasis. The 
ability to control energy homeostasis derives from the control of energy intake and 
energy expenditure and also has additional effects (Zhou et al., 2013). Apart from this it 
also plays a role in the endocrine and immune systems, including reproduction and 
glucose homeostasis. Some studies suggest that leptin plays an important role in the 
pathophysiology of cancer cachexia, since it is a proinflammatory cytokine that 
increases when infection is present and plays a role in CD4
+
 lymphocyte proliferation, 
macrophage phagocytosis and the secretion of IL-1 and TNF-α. Leptin binds to its 
receptor and activates different signalling pathways, such as the Janus Kinase/Signal 
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Transducer and Activator of Transcription (JAK/STAT), MAPK, phosphatidylinositol 
3-kinase/protein kinase B (PI3K/Akt), 5' AMP-activated protein kinase (AMPK) and 
insulin receptor substrate pathways (IRS), which affect cell proliferation and survival 
(Mantovani et al., 2000; Paz-Filho et al., 2011) .  
 Another cytokine with relevance in the regulation of WAT is ghrelin, a hormone 
mainly produced by the stomach and released into circulation in its acetylated and 
active form. Ghrelin has an important role in the induction of the growth hormone 
release, induction of adiposity, food intake and inhibition of the pro-inflammatory 
cytokines. In its active form it stimulates food intake by binding to the growth hormone 
secratagogue receptor (GHSR), located in the neurons of the hypothalamus, decreasing 
vomiting and nausea. This cytokine plays a role in the modulation of blood glucose 
levels and glucose disposal in the skeletal muscle and adipose tissue and is known to 
regulate lipid metabolism and lipid storage. Ghrelin also regulates the consumption of 
energy, through the inhibition of WAT browning and consequently, thermogenesis. 
Ghrelin levels correlate positively with various cachectic states, such as anorexia 
nervosa and severe congestive heart failure, and elevated levels of this hormone were 
recently reported to be associated with several types of cancer (Esposito et al., 2015; 
Sever et al., 2014 ). 
Adiponectin also plays a role in the pathogenesis of cachexia. The most 
important identified functions of adiponectin are anti-atherogenic, anti-inflammatory 
and insulin-sensitivity effects. There is increasing evidence that this adipokine is able to 
increase oxygen consumption and  thermogenesis, leading to weight loss (Kubota et al., 
2007).  It decreases lipid synthesis and the production of glucose in the liver (by 
decreasing gluconeogenesis), leading to a decrease in the blood concentrations of 
glucose and free fatty acids (Kubota et al., 2007).  
 The pathway that involves adiponectin and its receptors, AdipoR1 and AdipoR2 
mediates the activation of AMPK that plays a major role in the regulation of growth 
arrest and apoptosis. Activated AMPK works by stimulating p53 and p21. Independent 
of AMPK activation, adiponectin decreases the production of reactive oxygen species 
(ROS), leading to a reduced activation of mitogen-activated protein kinases (MAPK) 
and thereby inhibition of cell proliferation (Prieto-Hontoria et al., 2011; Candore, 2010 
). 
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3. Aims 
 
Cancer associated cachexia is recognized as a negative prognostic indicator. The 
metabolic changes that occur lead to the depletion of fat stores and skeletal muscle, 
resulting in body weight loss with negative impact on patient´s treatment response and 
quality of life. Aiming to add new insights on the mechanisms underlying cachexia in 
head and neck cancer, in the present thesis we intended to: 
i) Evaluate the potential association between BMI, nutritional status, tumour stage 
and location, and the incidence of cachexia; 
 
ii) Analyse the levels of metabolic parameters in head and neck cancer patients with 
and without cachexia; 
 
iii) Study the relation between inflammation and body wasting in head and neck 
cancer; 
 
iv) Analyse how the profile of hormones involved in the regulation of adipose tissue 
remodelling changes with cachexia; 
 
v) Study the contribution of the catabolic cytokine myostatin to the cachectic 
phenotype. 
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II. Materials and Methods 
 
II.I. Patient Selection 
 
Seventeen male patients diagnosed with head and neck cancer were enrolled in 
the present study, which was conducted between March and September 2016. Study 
protocol was approved by the Instituto Português de Oncologia do Porto Ethics 
Committee. The nature and purpose of the study was explained to participants before 
written informed consent was obtained. The eligibility criteria included patients: i) no 
obese and no diabetic; ii) no prior history of cancer; iii) with spinocellular tumors; iv) 
not submitted to prior cancer treatment; v) able to do unrestricted physical activity. 
Clinicopathological data was obtained from patients‘ clinical records. Among the 
information gathered by physicians from the Instituto Português de Oncologia do Porto 
was age, smoking and drinking habits, medication and tumors‘ stage. HNC tumours 
were histologically classified according to morphologic characteristic, concerning 
morphologically identifiable cell types and histological patterns that allow the 
identification of histogenesis of the tumor as epidermoid / squamous (Sobin, 1981).  
Tumour staging was done according to the International Union Against Cancer's 
(UICC) classification system for oral cancer (Sobin et al., 2011). All patients underwent 
nutritional evaluation and information regarding body mass index (BMI), Malnutrition 
Universal Screening Tool (MUST) and Patient-Generated Subjective Global 
Assessment (PG-SGA) scores were collected. MUST score uses several parameters to 
determine the risk of malnutrition in cancer patients, such as weight loss, BMI, serum 
albumin concentration, questions about food intake, being completed by professionals. 
The PG-SGA evaluation  comprises medical history, weight loss, nutrition, food intake, 
among others, and is completed by the patient (Gorenc et al., 2015). This tool was 
specifically designed to assess malnutrition in oncology and results from the adaptation 
of the Subjective Global Assessment (SGA or Detsky index), which allows a simple and 
reproducible classification of patients into three groups: (A) well nourished, (B) 
moderate or suspected malnutrition, (C) severe malnutrition (Detsky et al., 1987).  One 
of the strong points of the PG-SGA tool is that, in addition to recent weight loss, 
assessment of nutritional status includes symptoms such as loss of appetite, nausea, 
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swallowing difficulties, etc., the patient's dietary intake and functional capacities 
(Detsky et al., 1987). 
Patients were assigned to one of two groups according to the percentage of body 
weight loss reported in the last 6 months. Patients that reported a weight loss higher 
than 5% were included in the head and neck cancer + cancer cachexia (HNC+CC) 
group whereas patients with no weight loss or weight loss lower than 5% in 6 months 
were included in the head and neck cancer with no cachexia (HNC) group. At the end, 
six patients were enrolled in the HNC group and 11 subjects in the HNC+CC group.  
 
II.II Blood Collection and biochemical measurements 
 
Blood samples were collected in the morning at IPO-Porto. No fasting was 
required to patients. Blood samples were allowed to clot for one hour and then 
centrifuged at 4000g during 10 minutes. The supernatant was collected and stored at -
20ºC until analysis.  
The biochemical parameters glucose, urea, cholesterol, triglycerides, total 
protein and albumin were measured using an automated analyzer (AU500 Clinical 
Chemistry Analyzer, Beckman Coulter, Inc) and C-reactive protein was determined by 
an immune-turbodimetric technique using an automated analyzer (Beckman Coulter 
AU). These analyses were performed at IPO-Porto. The levels of cytokines and 
hormones were assessed by immunoblot as described in the following subsection.  
 
 
II.III. Immunoblot assessment of serum levels of cytokines 
 
 Serum samples were diluted in Tris buffered saline (TBS; 100 mM Tris, 1.5 mM 
NaCl, pH 8.0) and 100 µL was slot-blotted into a nitrocellulose membrane (Whatman, 
Protan) under vacuum after membrane activation in 10% methanol. The effectiveness of 
this procedure was confirmed by membrane staining with Ponceau S. Then, membranes 
were incubated with 5% (w/v) dry nonfat milk in TBS-T (TBS with 0.5% Tween 20) to 
avoid nonspecific binding. The membranes were then incubated with a primary 
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antibody, diluted 1:1000 in 5% (w/v) dry nonfat milk in TBS-T (mouse monoclonal 
anti-adiponectin, ab22554, Abcam; rabbit monoclonal anti-leptin, ab16227, Abcam; 
mouse monoclonal anti-ghrelin, ab64325, Abcam; mouse monoclonal anti-TWEAK, 
ab37170l, Abcam; rabbit polyclonal anti-GDF8 (myostatin), ab996, Abcam) at room 
temperature for two hours. The membranes were then washed with TBS-T (3 times, 10 
min each time) and incubated with anti-mouse or anti-rabbit secondary antibody, 
conjugated with horseradish peroxidase (GE Healthcare), depending on the primary 
antibody. Chemiluminescence ECL (Amersham Pharmacia Biotech) was used to detect 
immune-reactive bands, according with the manufacturer´s instructions. The images 
were then recorded using X-ray films (Kodak Biomax Light Film, Sigma, St. Louis, 
MO,USA), a procedure performed in a dark room. Films were scanned in Molecular 
Imager Gel Doc XR+System (Bio-rad) and analyzed with ImageLab (v 5.0 Bio-Rad). 
 
II.I.V. Statistics 
 
An exploratory data analysis was initially conducted using graphical techniques 
(bar charts, box and scatter plots) and a quantitative analysis (statistical measures) was 
performed in order to characterize each group, detect possible extreme outliers and 
measurement error. In order to identify the alterations between patients with and 
without cachexia, tests of the equality of means for independent samples were 
conducted: Mann-Whitney test (the assumptions of the tests were performed). Statistical 
analysis was conducted using IBM SPSS Statistics Software 22. Results were 
considered significantly different when p<0.05. Values are presented as mean ± 
standard deviation for all variables.  
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III. Results and discussion 
 
 In order to add new insights on the molecular mechanisms underlying HNC 
cachexia, two groups of cancer patients were considered in the present study. The 
information regarding age, body mass index (BMI), lifestyle and disease stage in each 
group of patients is overviewed in table 1.  
As can be depicted in table 1, patients from both groups present BMI higher than 
20 Kg/m
2
 but lower than 25 Kg/m
2
 suggesting that all cancer patients are lean. The BMI 
values in the group HNC+CC was somehow unexpected once according to Fearon 
(Fearon et al., 2011) cachexia is characterized by a BMI inferior to 20 Kg/m
2
. However, 
water accumulation as a consequence of hypoalbuminemia might affect BMI 
(Muscaritoli et al., 2010; Tisdale, 2002). Indeed, lower levels of serum albumin were 
noticed in HNC+CC patients (figure 10). So, our data suggest that BMI might not 
discriminate cachexia in HNC patients. 
The risk of cachexia´s progression was previously suggested to be dependent on 
cancer type and stage (Fearon et al., 2011). All cancer patients enrolled in the present 
study evidenced squamous cell carcinoma mostly located at oropharynx and 
hypopharynx, at T3 and T4 stages of disease, with staging being done according to the 
International Union Against Cancer's (UICC) classification system for oral cancer 
(Sobin et al., 2011). Squamous cell cancer of the head and neck is one of the most 
common cancers worldwide, constituting the fifth cause of death with cancer among 
men in Portugal (Silveira et al., 2010). It has been reported that patients with 
hypopharyngeal cancer had the worst health related quality of life score, compared with 
tumours at other sites within the head and neck, and that stage had the strongest impact 
(Sanderson et al., 2002). In the present study, the percentage of patients with tumours of 
greater dimensions and advanced local disease (T4 stage) was higher in HNC+CC than 
in HNC group (91 vs 67%, respectively; table 1). Curiously, the percentage of patients 
with lymph nodes metastasis (N2 and N3) was lower in HNC +CC than in HNC group. 
However, the number of patients in each group, particularly in HNC group, is low 
which might biased the association between disease stage and cachexia risk.  
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Table 1. Baseline patient characteristics in each group 
 
Patients’ 
characteristics 
Group 
HNC+CC 
         (n=11) 
HNC 
(n=6) 
Age (years) 52.0 ± 5.37 55.7 ± 3.61 
Body mass index 
(Kg/m
2
) 
21.64 ± 1.52 22.33 ± 4.41 
Tumour location (%) 
 
Oral cavity (27) 
Oropharynx (37) 
Hypopharynx (27) 
Larynx (9) 
Nasopharynx (0) 
 
 
Oral cavity (0) 
Oropharynx (33) 
Hypopharynx (33) 
Larynx (17) 
Nasopharynx (17) 
Disease stage (%) 
T 
N 
M 
 
T2 (0); T3 (9); T4 (91) 
N0 (25); N1 (17); N2 (50); N3 (8) 
M0 (91); M1 (9 
 
T2 (0); T3 (33); T4 (67) 
N0 (0); N1 (16); N2 (67);  N3 
(17) 
M0 (100); M1 (0) 
Smoking habits 
 
Over 20 cigarettes/day Over 20 cigarettes/day 
Drinking habits (%) Moderate (0) 
Heavy (100) 
 
Moderate (80) 
Heavy (20) 
Medication 
(n=17) 
Angiotensin converting enzyme 
inhibitors (n=2) 
Proton pump inhibitors (n=1) 
Semisynthetic opioid (n=1) 
Nonsteroidal antiflammatory goup 
Statins group 
Benzodiazepines group (n=2) 
Angiotensin II receptor antagonis 
(n=1) 
Calcium channel blocker  (n=1) 
Angiotensin converting enzyme 
inhibitors (n=1) 
Proton pump inhibitors (n=1) 
Synthetic opioid 
(aminocyclohexanol group) 
(n=1) 
Calcium channel blocker  (n=1) 
Miscellaneous analgesic (n=2) 
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 There is evidence of a marked association between smoking and drinking habits 
and the development of head and neck cancer (Leemans et al., 2011). The results 
obtained support this association by demonstrating that both groups present strong 
drinking and smoking habits. People who use both tobacco and alcohol are at greater 
risk of developing these cancers than people who use either tobacco or alcohol alone 
(Pelucchi et al., 2006). Tobacco smoke and alcohol consumption are associated with 
oxidative damage of DNA. The tobacco carcinogen benzo[α]pyrene diol epoxide 
(BPDE) seems to promote genetic damage by forming covalently bound DNA adducts 
throughout the genome, including p53 (Serpi, 2003). Damage promoted by tobacco 
carcinogens might be repaired by the nucleotide excision repair (NER) system and also 
by the base excision repair (BER) system. So, individual variations in NER/BER might 
influence tobacco smoking related cancer risks (Health & Services, 2010). The 
oxidative damage of DNA induced by exposure to carcinogenic factors and not repaired 
by NER or BER systems may lead to the abnormal expression of tumour suppressor 
genes and/or proto-oncogenes, which in turn, activate pathways that lead to the 
malignant transformation of cells (Reuter, 2010). Even though implicated in the 
aetiology of head and neck cancer, there is no evidence of the association between 
smoking and drinking habits with the development and progression of cachexia.  
 Not all patients were taking medication at the time, only 3 patients in each group 
were medicated. In the HNC+CC group the medicated patients were being treated for 
elevated levels of cholesterol and triglycerides, depression and anxiety, gastric 
problems, hypertension and addictions, namely alcohol. In the HNC group they were 
being treated for hypertension, gastric problems and pain. A study of the literature 
showed that the medication that could interfere with cachexia is the calcium chain 
blockers and angiotensin converting enzyme inhibitors that are known to suppress 
sympathetic activity, and to lower leptin levels. Therefore, patients who were under this 
medication might present lower leptin levels than expected (Masuo et al., 2001). 
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III.I. Nutritional parameters evaluation 
 
HNC patients are frequently malnourished at the time of diagnosis and prior to 
the beginning of treatment, which determines the patient's tolerance to curative 
treatment. So, nutritional counselling is usually considered in the multidisciplinary 
standard of care of these patients (Bossola, 2015). Many screening tools for nutritional 
risk have been published (Green et al., 2005), but no consensus has been reached 
concerning their use. In IPO-Porto, MUST (Malnutrition Universal Screening Tool) 
score and PG-SGA (Patient-Generates Subjective Global Assessment) are the tools 
implemented in the nutritional counselling. MUST score uses several parameters to 
determine the risk of malnutrition in cancer patients, such as weight loss, BMI, serum 
albumin concentration, questions about food intake, being completed by professionals. 
The PG-SGA evaluation  comprises medical history, weight loss, nutrition, food intake, 
among others, and is completed by the patient (Gorenc et al., 2015). This tool was 
specifically designed to assess malnutrition in oncology and results from the adaptation 
of the Subjective Global Assessment (SGA or Detsky index), which allows a simple and 
reproducible classification of patients into three groups: (A) well nourished, (B) 
moderate or suspected malnutrition, (C) severe malnutrition (Detsky et al., 1987).  One 
of the strong points of the PG-SGA tool is that, in addition to recent weight loss, 
assessment of nutritional status includes symptoms such as loss of appetite, nausea, 
swallowing difficulties, etc., the patient's dietary intake and functional capacities 
(Detsky et al., 1987). 
Figure 9 shows a clear association between the MUST score and PG-SGA 
results. An elevated risk of malnutrition was observed in the HNC+CC group, with a 
MUST score superior to 2 and a PG-SGA score of B and C. In contrast, the HNC group 
showed that all the patients present a low risk of malnutrition, with a MUST score of 0 
or 1 and a PG-SGA score of A. Head and neck cancer patients have one of the highest 
malnutrition rates (25-50%) in the oncologic set, even before starting treatment (Mason 
et al., 2016). The tumour location and the progression of the disease might cause 
reduced food intake and malnutrition due to dysphagia and xerostomia (Gorenc, 2015). 
The comparison of our results given by these tools with BMI data, suggests that other 
factors must influence BMI among cachectic patients, since there is a significant 
difference between BMI and MUST score and PG-SGA results. 
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III.II Analysis of biochemical parameters 
 
 
In order to better characterize the metabolic alterations underlying CC in HNC 
we analysed serum levels of glucose, total protein, total cholesterol and triglycerides 
and the results obtained are presented in table 2. All the results were in the normal range 
(compared to reference values).  
 
 
11% 
11% 
56% 
11% 
11% 
Must score HNC+CC 
0 1 2 3 4
50% 50% 
Must score HNC  
0 1
14% 
43% 
43% 
PG-SGA HNC+CC 
A B C
100% 
0% 
PG-SGA HNC 
A B C
Figure 9. MUST score evaluation of the HNC+CC (n=9) and HNC (n=4) groups; score =0 
represents low risk of malnutrition; score = 1 represents a medium risk of malnutrition; 
score≥ 2 represents high risk of malnutrition. PS-SGA global evaluation of the patients in 
the HNC+ CC (n=7) and HNC (n=3) groups:  A score = well nourished; B score = slightly 
malnourished; C score = highly malnourished. 
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Table 2. Evaluation of serum levels of glucose, total protein, total cholesterol and triglycerides in 
HNC+CC and HNC groups. 
 HNC+CC 
(n=11) 
HNC 
(n=6) 
Glucose (mmol/L) 5.57 ± 0.53 4.98 ± 0.69 
Total protein (g/L) 74.83 ± 4.78 
 
72.16  ± 3.13 
 
Total cholesterol (mmol/L) 4.32 ± 0.77 5.24 ± 1.27 
Triglycerides (mmol/L) 1.16 ± 0.27 1.66 ± 0.91 
 
No differences in the levels of these biochemical parameters were observed 
among groups, which do not support the metabolic alterations reported in CC. Even so, 
the trend to higher serum glucose levels noticed in HNC + CC patients (table 2), might 
reflect the Cori cycle increased activity between the host and the tumour, in order to 
maintain the metabolic needs (Friesen, 2015; Esper, 2005; Keller, 1993). Glucose is 
metabolized by the tumour via glycolysis, and a major consequence of this metabolism 
is the release of lactate into circulation. Once in circulation, the lactate is transported to 
the liver where the carbon skeleton is used to synthesize glucose through 
gluconeogenesis that might be released from the liver to support tumor‘s metabolic 
needs, in the so called Cori cycle  (DeWys, 1982; Giordano et al., 2003). There is 
evidence that, in the presence of cachexia, the Cori cycle metabolizes half of all glucose 
available and 60% of all lactate disposals (Esper et al., 2005). In addition to lactate, also 
alanine and glycerol serum levels are expected to be elevated in cachexia, due to the 
metabolic changes in protein metabolism. These metabolites are used to produce 
glucose in the liver through gluconeogenesis (Fearon, 2012). 
Focusing on cholesterol and triglycerides serum levels, data obtained (table 2) 
suggests no cachexia-related lipolysis of the adipose tissue as previously suggested 
(Bing et al., 2004; Das et al., 2011; Ebadi et al., 2015; Legaspi et al.,  1987). Indeed, 
when there is lack of energy, the adipose tissue releases free fatty acids derived from 
stored triglycerides (Ebadi et al., 2014), as a consequence of increased ATGL and HSL 
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activities (Bing et al., 2004; Das et al., 2011; Ebadi et al., 2015). Lipid mobilization is 
prompted by the increased circulation of several factors, such as the adipokine ZAG, 
LMF, IL-1, IL-6 and TNFα (Porporato, 2016). Both LMF and ZAG produce specific 
loss of body fat with a tendency to increase lean body mass, this effect appears to be due 
to interaction with a β-adrenergic receptor. Loss of adipose tissue was coupled with an 
increase in expression of UCP1 in BAT and consequent increase in energy expenditure 
(Tisdale, 2005). Also the released fatty acids serve as an energy source for heat 
production in BAT, showing a correlation between the remodelling of adipose tissue 
with increased energy expenditure and WAT browning (Tisdale, 2005). 
In order to evaluate the contribution of inflammation to the metabolic profile of 
head and neck cancer patients we measured the serum levels of albumin, CRP and 
TWEAK (figure 10). Inflammation has a major role in the development of cancer 
cachexia. It is known that in response to tissue injury an acute-phase response begins, 
leading to an increased production of acute-phase proteins (Argilés et al., 2005). In the 
present study no alterations of serum CRP levels were observed among groups 
(p=0.291), which might explain the BMI variation among groups, considering the 
positive correlation between BMI and CRP levels previously reported (Md, 2007). 
Nevertheless, lower levels of serum albumin were observed in HNC+CC group, though 
not statistically significant (p= 0.067; figure 10). So our data do not apparently support 
the association between inflammatory markers and weight loss, due to the spill over 
effects of excessive cytokine production by tumours (Tsoli et al., 2013). 
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The presence of tumour is expected to be associated with persistent host 
inflammatory response, which is associated with hypermetabolism (Noguchi et al., 
1996). Among the alterations that cachexia induces in the body, the liver exhibits some 
marked changes in the pattern of protein synthesis. This changes include increased 
production of acute-phase proteins, including CRP, and a decrease in the production of 
albumin, leading to a state of hypoalbuminemia that must be due  to increased 
transcapillary escape and increased degradation (Argilés et al.,  2015;  Fearon et al., 
2012). The production of acute-phase proteins leads to a mismatch in amino acid 
composition between skeletal muscle and acute phase proteins and it has been suggested 
that during a low food intake this may amplify the need for muscle mobilization, 
therefore the acute-phase response  may accelerate muscle wasting in cachectic cancer 
patients (Fearon et al., 2012).  
Curiously, no differences of TWEAK levels were noticed among groups. 
TWEAK is a pro-inflammatory cytokine from the TNF superfamily that acts by binding 
TWEAK 
Figure 10. Variation of C-reactive protein and albumin levels in serum samples from both groups. 
Variation of TWEAK levels in serum samples evaluated by immunoblot from patients in both groups. 
Under the graph is shown a representative image of immunoblot data. The values (mean± SD) are 
expressed in mg/L, g/L and arbitrary units of optical density (OD).  
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to Fn14 (Schiaffino et al., 2013). TWEAK and its ligand Fn14 induce pro-inflammatory 
responses by stimulating the expression of chemokines, cytokines, adhesion molecules 
and MMPs. Muscle wasting involves the degradation of selective muscle proteins, such 
as myosin heavy chain (MHC). TWEAK was found to increase the expression of 
muscle-specific E3 ubiquitin ligases MuRF1 and MAFbx and stimulates the conjugation 
of ubiquitin with MyHC, suggesting that TWEAK causes degradation of MHC through 
the activation of UPS (Bhatnagar et al., 2012). There is also evidence of TWEAK 
cooperating with TNF-α to increase the inflammatory response and TWEAK also 
activates both the classical and alternative NF-kB signalling pathways and  induces the 
expression of NF-kB-regulated proinflammatory cytokines and cell adhesion molecules, 
suggesting that TWEAK might mediate inflammatory responses (Dogra et al., 2007; 
Londhe et al., 2015). Our results do not apparently support the inflammation in the 
development and progression of cachexia in head and neck cancer and its connection 
with the metabolic changes that cachectic patients undergo. 
In order to evaluate the contribution of adipose tissue remodelling to CC, we 
evaluated the serum levels of the hormones leptin, ghrelin and adiponectin (figure 11). 
Adipokines yield significant effects on metabolism and lipogenesis as well as in the 
regulation of human inflammatory responses (Karapanagiotou et al., 2008).  
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Our results do not evidence differences of serum leptin levels among groups (p 
=0.078; figure 14), neither of serum ghrelin content (p=0.151). Leptin is a member of 
the cytokine family and is an important signalling molecule in the energy regulation 
(Begenik et al., 2015). Leptin is predominantly expressed in the adipose tissue and 
signals in the hypothalamus the status of fat stores, playing a significant role in energy 
homeostasis (Begenik et al., 2015; Mak, 2014 ). Despite the importance of 
hypothalamic mediation of leptin actions, there is evidence that, at least at high 
concentrations, leptin acts directly on white adipocytes, by stimulating lipolysis and 
inhibiting lipogenesis (Orci et al., 2004; Balistreri, 2010 ). There is also evidence of 
leptin´s involvement in the inflammatory response, carcinogenesis and to the impaired 
glucose metabolism (Prieto-Hontoria et al., 2011; Morton, 2007). Ghrelin exerts 
Leptin Ghrelin 
Figure 11. Variation of leptin, adiponectin and ghrelin levels in serum samples from both groups, 
evaluated with immunoblot. Under the graph is shown a representative image of immunoblot data. 
The values (mean± SD) are expressed in units of optical density (OD).  
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antagonistic effects on the leptin-induced decrease in food intake through activation of 
the hypothalamic neuropeptide Y-Y1 (NPYY1) pathway (Takahashi et al., 2009). It is 
known for regulating fat mass by decreasing the level of neuropeptide Y in the 
hypothalamus, and consequently decreasing food intake (Takahashi et al., 2009). It has 
been reported that ghrelin levels increase under conditions of fasting or low BMI (Sever 
et al., 2016). Under fasting conditions, the stomach secretes ghrelin into the 
bloodstream to act a ―hunger‖ mediator that signals the gastrointestinal fuel status from 
the periphery to the central nervous system in order to stimulate food intake and to 
adjust energy balance through decreasing energy expenditure. This decrease in energy 
expenditure is achieved by activating white adipocytes (Müller et al., 2010). Ghrelin has 
also been shown to cause a positive energy balance and weight gain, by decreasing fat 
utilization and increasing carbohydrate utilization, and to have anti-inflammatory effects 
since it decreased serum levels of IL-6 (DeBoer et al., 2007; Shimizu, 2003 ). The 
absence of an association between CC and ghrelin levels in our study might reflect the 
similarities observed in BMI among groups (table 1).  
We also found no differences in the serum levels of adiponectin among groups. 
Adiponectin is produced and secreted exclusively by the adipose tissue. Therefore, 
alterations in adipose tissue, a compensatory response to inflammation and the 
development of insulin resistance can lead to alterations in the expression levels of this 
adipokine (Kemik et al., 2012; Donatto, 2013 ; Smiechowska et al., 2010). There is 
growing evidence that adiponectin modulates the production of other cytokines, and is 
able to activate AMP kinase to stimulate glucose uptake and fatty acids oxidation in the 
skeletal muscle, decreasing the influx of fatty acids to the liver and the total triglyceride 
content and decrease vascular inflammation (Bing et al., 2010; Dalamaga et al., 2012). 
In CC, it has been reported decreased levels of adiponectin as a reflex of adipose tissue 
wasting (Diakowska, 2014). So, our data regarding serum levels of cytokines involved 
in WAT browning (figure 11) do not support adipose tissue remodelling in head and 
neck cancer cachexia.  
WAT remodelling seems to precede skeletal muscle catabolism in cancer 
cachexia (Petruzzelli, 2016). So, we analysed the levels of serum myostatin in order to 
verify if at this stage of disease muscle catabolism has a major contribution to CC than 
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WAT remodelling. In figure 12 we can see that serum myostatin levels are significantly 
higher in HNC+CC patients (p =0.037).  
                         
 
 
 
 
Myostatin, a member of the transforming growth factor-β superfamily, is almost 
exclusively expressed in the skeletal muscle, where it negatively regulates myocyte 
differentiation/growth and determines muscle size (Liu et al., 2008; Skipworth, 2007 ).  
It has been implicated in several forms of muscle wasting, including cancer cachexia 
and has been proposed to negatively regulate skeletal muscle mass (Mueller et al., 2016; 
Costelli, 2008 ). Binding of free myostatin to the Activin type IIB receptor (ActRIIB) 
results in the activation of transcription factors belonging to the SMAD family, although 
myostatin might also signals through other pathways, such as the Extracellular signal-
Regulated Kinase (ERK)/Mitogen Activated Protein Kinase (MAPK) cascade (Costelli 
et al., 2008). Myostatin is increased upon inflammatory signalling, whereas it inhibits 
myoblast differentiation and increased FOXO3 activation (Zhou et al., 2010; 
Petruzzelli, 2016 ). The overexpression of this catabolic cytokine also affects the 
adipose tissue, where both reductions and increases in the size of adipocyte have been 
reported (Costelli et al., 2008). The absence of myostatin, as for instance in knockout 
mice (Mstn
-/-
) leads to increased muscle mass and drives browning of WAT indirectly 
Figure 12. Variation of myostatin levels in serum samples from both 
groups, evaluated immunoblot. Under the graph is shown a 
representative image of immunoblot data. The values (mean± SD) are 
expressed in arbitrary units of optical density (OD). (*p<0.05) 
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through the AMPK-peroxisome proliferator-activated receptor g co-activator 1a-
fibronectin type III domain-containing 5 signalling (Shan, 2013). This increase in 
myostatin levels supports cachexia-related muscle wasting, and precludes changes in 
adipose tissue metabolism, though not supported by alterations in adipokines‘ levels. 
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IV. Conclusions and future perspectives 
 
In the present study, we set out to disclose the molecular mechanisms underlying 
cachexia in head neck cancer through the analysis of serum samples and its association 
with anthropometric data and tumour stage. Our results allowed us to conclude that: 
i. BMI and tumour stage do not apparently relates with the establishment of 
cachexia in head and neck cancer, based on weight loss higher than 5% in 6 
months reported by patients. Nevertheless, MUST and PG-SGA scores support a 
higher risk of malnourishment in patients from HNC+CC group. 
ii. There are no apparent metabolic changes associated with HNC cachexia despite 
a trend to higher glucose levels, not supporting cachexia-related adipose tissue 
remodelling and muscle wasting.  
iii. Inflammation does not seem to distinguish cachectic from non-cachectic patients 
in the set of head and neck cancer, given by CRP, TWEAK and albumin levels.  
iv. The serum levels of the adipokines leptin and adiponectin and of the gastric 
hormone ghrelin do not evidence the contribution of WAT remodelling to head 
and neck cancer-related body weight loss.  
v. The significantly higher serum levels of myostatin in the HNC+CC group 
supports the contribution of muscle wasting to the cachexia phenotype in head 
and neck cancer patients. 
Taken together, our results support the contribution of muscle wasting but not of 
WAT remodelling to the development of cachexia in the set of head and neck cancer. 
Nevertheless, future studies should be performed involving a higher number of patients 
to better support our molecular and antropometric findings envisioning to improve the 
clinical management of patients in risk of cachexia. We believe that it will also be 
important to include information regarding body composition, such as evaluation of 
adipose folds and DEXA, and other experimental groups, such as a group of patients 
with pre-neoplasic lesions and a group of smokers with no cancer to better follow WAT 
remodelling and its interplay with muscle wasting in the pathogenesis of head and neck 
cancer. Focus should continue to be given to the molecular pathways underlying cancer 
cachexia envisioning to improve patients‘ response to therapeutics, quality of life and 
survival.  
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VI. Appendix 
 
 
Table 3. Table with the clinical information, concerning patient number, weight loss, tumour stage and location, MUST score, and 
serum levels of  glucose, cholesterol, triglycerides, total protein, albumin and C-reactive protein of HNC+CC and HNC patients 
 
 
 
 
HNC+CC 
Patient 
Number 
Weight 
Loss (Kg) 
Tumour stage and 
location 
Must 
score 
Glucose 
(mmol/L) 
Cholesterol 
(mmol/L) 
Triglycerides 
(mmol/L) 
Total 
protein 
(g/L) 
 
Albumin 
(g/L) 
CRP 
(mg/L) 
4 9 (in 5 
months) 
pT4N2c tongue 3 5.9 4.55 1.14 68 45 1 
1 7 (in 3 
months) 
cT4N3M0 
oropharynx 
0 5.2 4.92 1.20 73 43 40.1 
2 14 (in 2 
months) 
cT4N2M0 
nasopharynx 
2 5.3 3.48 1.71 76 40 9.30 
8 12 (in 6 
months) 
cT4N1M0 base of 
the tongue 
0 6.1 No data No data 76 43 71.7 
9 6 (in 6 
months) 
cT2N2M0  piriform 
sinus 
1 5.5 3.89 0.78 74 34 145.9 
11 5 (in 5 
months) 
cT4N2M1 
SUPRAGLOTE 
No 
data 
6.1 4.69 1.30 73 41 17.7 
12 6 (in 6 
months) 
cT3N2M1 Posterior 
pharynx wall 
2 5.5 5.92 1.25 75 43 14.9 
5 10 (in 6 
months) 
cT4N0M0  
oropharynx 
No 
data 
5.9 3.59 0.91 80 28 34.1 
15 27 (in 4 
months) 
cT4N2M0  tongue 4 5.3 3.80 1.31 66 36 55.7 
17 3 (in 1 
month) 
cT4N0M0  piriform 
sinus 
1 4.4 5.47 0.91 82 37 4.40 
18 8 (in 3 
months) 
cT3N2M0  base of 
the tongue 
No 
data 
6.3 3.53 0.87 81 31 5.40 
HNC 
10 1 (in 2 
months) 
T3N2M0  pharynx 0 6.3 5.57 1.01 73 42 7.82 
6 2 (in 6 
months) 
cT4N2M0  
pharyngolaryngeal 
 
0 4.7 6.66 3.38 71 46 1.90 
13 0 (in 8 
meses) 
cT2N1M0 
SUPRAGLOTE 
0 4.8 6.00 1.76 77 47 2.10 
7 0.5 (in 7 
months) 
cT4N2M0  
nasopharynx 
No 
data 
4.3 5.60 0.89 69 45 0.80 
3 1 (in 3 
months) 
cT4N3M0 h 
hypopharynx 
1 4.8 4.49 1.32 74 42 47 
14 0 (in 6 
months) 
cT3N2M0 
amygdala 
1 5 3.09 1.59 69 36 58.2 
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